Skip to main content
TipRanks
Go Ultimate75% OFF

Bioline RX Ltd Sponsored ADR (BLRX) AI Stock Analysis

2,554 Followers
BLRX

Bioline RX Ltd Sponsored ADR

(NASDAQ:BLRX)

Select Model
Rating:44Neutral
Price Target:$1.00â–¼(-13.04% Downside)
Action:reiterated
Date:11/17/26

BLRX scores low primarily due to very weak financial performance (large losses, declining revenue, and ongoing cash burn) and strongly bearish technicals with the stock far below key moving averages. The latest earnings call adds some support via encouraging GLIX1 progress and a stated cash runway into 1H27, but negative earnings and limited valuation support (negative P/E, no dividend) keep the overall score subdued.

Positive Factors
GLIX1 clinical progressGLIX1 is advancing through early clinical development with continued cohort dosing and no significant treatment-emergent adverse events reported. This supports initial safety and execution, while the program’s progression creates a potential future growth driver beyond APHEXDA if clinical activity is confirmed.
Negative Factors
Persistent losses and cash burnBioLineRx remains materially loss-making and consumes cash rather than funding operations internally. Continued burn can reduce strategic flexibility, require additional capital, and increase dependence on financing or partnership proceeds before pipeline assets generate meaningful recurring revenue.

Bioline RX Ltd Sponsored ADR (BLRX) vs. SPDR S&P 500 ETF (SPY)

-80%-60%-40%-20%0%20%BLRX-65.47%SPY+13.31%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$5.72M
Dividend Yield
―
Average Volume (3M)
17.66K
Price to Earnings (P/E)
-1.0
Beta (1Y)
1.35
Revenue Growth
-91.94%
EPS Growth
55.29%
Country
US
Employees
22
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Bioline RX Ltd Sponsored ADR Business Overview & Revenue Model

Company Description

BioLineRx Ltd., an Israeli biopharmaceutical firm established in 2003 and based in Hevel Modi'in, focuses its clinical-stage development efforts primarily on oncology. Their leading investigational product, Motixafortide, a peptide, has successfully...

How the Company Makes Money

BiolineRx makes money primarily through commercialization-related revenue from its approved product APHEXDA (motixafortide), where revenue is generated from product sales (directly and/or via commercial partners, depending on territory and distributi...

Bioline RX Ltd Sponsored ADR Earnings Call Summary

Earnings Call Date:Aug 31, 2026(Q2-2026)|% Change Since:-55.77%|Next Earnings Date:May 27, 2025
Earnings Call SentimentPositive

The call was broadly positive, driven by strong GLIX1 clinical enrollment and early safety and tolerability, encouraging glioblastoma and ovarian-cancer preclinical results, continued PDAC trial enrollment, APHEXDA royalty generation, and a cash runway extending into the first half of 2027. Offsetting points included a higher quarterly net loss, flat revenue, uncertainty around the evolving PDAC treatment landscape, and the substantial work still required to expand APHEXDA adoption.

Positive Updates

GLIX1 Clinical Trial Progress
BioLineRx initiated the Phase I/IIa GLIX1 trial in March, dosed the first patient in April at NYU Langone Health, and has since enrolled patients at Northwestern University and Moffitt Cancer Center. Recruitment is progressing extremely well and according to plan; dosing has begun in the second of five planned Phase I cohorts, with the third cohort expected to commence dosing in September. The company reported that GLIX1 has shown very good safety and tolerability a little more than four months into the study and continues to anticipate Phase I data in the first half of 2027.

Negative Updates

Quarterly Net Loss Increased
Net loss for the quarter ended June 30, 2026, was $4.3 million compared with $3.9 million in the 2025 quarter, an increase of $0.4 million or approximately 10.3%.

Company Guidance

BioLineRx expects the third of 5 planned GLIX1 Phase I cohorts to commence dosing in September, with the Phase I part expected to recruit up to 30 patients and Phase I data anticipated in the first half of 2027; the Phase IIa expansion is planned to include additional cohorts, including GBM, newly diagnosed and/or recurrent, as well as additional cancers with or without standard of care, for example, PARP inhibitors. The CheMo4METPANC trial’s prespecified interim/futility analysis is planned when 40% of progression-free survival events are observed, expected later this year. Cash and equivalents of $13.1 million are sufficient to fund the operating plan as currently contemplated into the first half of 2027, and the $3.75 million offering is expected to close later today.

Bioline RX Ltd Sponsored ADR Financial Statement Overview

Summary

Financials are very weak: deeply negative profitability (net margin about -572%), shrinking TTM revenue (~-35%), and continued cash burn (TTM operating/free cash flow roughly -$10.9M). The balance sheet leverage is moderate for biotech (debt-to-equity ~0.58, improving vs. 2024), but negative ROE (~-47%) and ongoing losses keep overall financial strength low.

Income Statement

22Negative

Balance Sheet

46Neutral

Cash Flow

18Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Mar 2025Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue1.40M1.19M28.94M4.80M00
Gross Profit976.26K430.39K19.68M1.11M00
EBITDA-8.26M-224.77K3.92M-57.09M-22.14M-25.37M
Net Income-8.03M-1.18M-9.22M-60.61M-24.95M-27.05M
Balance Sheet
Total Assets33.48M40.90M38.91M63.92M76.38M81.39M
Cash, Cash Equivalents and Short-Term Investments13.08M20.88M19.56M42.99M51.08M57.13M
Total Debt7.94M10.15M15.04M11.59M12.32M4.65M
Total Liabilities16.86M17.56M25.45M50.70M25.54M13.30M
Stockholders Equity13.77M18.20M13.46M13.22M50.84M68.09M
Cash Flow
Free Cash Flow-10.90M-8.16M-43.93M-22.91M-26.56M-23.67M
Operating Cash Flow-10.88M-8.14M-43.87M-22.61M-26.24M-23.57M
Investing Cash Flow12.45M-8.61M29.37M1.44M4.01M-38.22M
Financing Cash Flow-4.51M8.95M20.66M15.06M20.44M57.75M

Bioline RX Ltd Sponsored ADR Technical Analysis

Technical Analysis SentimentNegative
Last Price1.15

Price Trends

50DMA2.14Negative
100DMA2.50Negative
200DMA2.66Negative

Market Momentum

MACD-0.25Positive
RSI11.61Positive
STOCH0.43Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BLRX, the sentiment is Negative. The current price of 1.15 is below the 20-day moving average (MA) of 1.80, below the 50-day MA of 2.14, and below the 200-day MA of 2.66, indicating a bearish trend. The MACD of -0.25 indicates Positive momentum. The RSI at 11.61 is Positive, neither overbought nor oversold. The STOCH value of 0.43 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BLRX.

Bioline RX Ltd Sponsored ADR Risk Analysis

Bioline RX Ltd Sponsored ADR disclosed 43 risk factors in its most recent earnings report. Bioline RX Ltd Sponsored ADR reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

0 New Risks

Bioline RX Ltd Sponsored ADR Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

BLRX against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
AEONAEON45Neutral$8.31M-0.04204.18%――35.03%
BLRXBLRX44Neutral$9.21M-0.99-47.22%―-91.94%55.29%
CTXRCTXR43Neutral$14.48M-0.25-67.15%――57.48%
GTBPGTBP43Neutral$7.29M-0.03-443.08%――75.09%
DAREDARE41Neutral$11.49M-0.77-748.08%―――
KALAKALA41Neutral$2.47M-0.00-222.32%――78.25%

* Healthcare Sector Average

Performance Comparison

-100%-50%0%50%BLRXDAREGTBPKALACTXRAEONDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
BLRX and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
BLRXBioline RX Ltd Sponsored ADR1.15-2.06-64.17%
DAREDaré Bioscience0.58-1.20-67.19%
GTBPGt Biopharma, Inc.3.54-12.85-78.43%
KALAKala Bio, Inc.3.83-1029.37-99.63%
CTXRCitius Pharma0.53-0.54-50.75%
AEONAeon Biopharma, Inc.0.14-0.82-85.42%

Bioline RX Ltd Sponsored ADR Corporate Events

BioLineRx Presents GLIX1 Clinical and Preclinical Data at SNO 2026

Nov 16, 2026

BioLineRx is a clinical-stage biopharmaceutical company pursuing therapies in oncology and rare diseases, with GLIX1 as its lead development asset and APHEXDA as its approved product for stem-cell mobilization in multiple myeloma. On November 16, 202...

BioLineRx and Hemispherian Report GLIX1–PARP Inhibitor Synergy in HR-Proficient Ovarian Cancer

Oct 23, 2026

On October 23, 2026, BioLineRx and Hemispherian reported preclinical data presented at the ESMO 2026 congress showing that GLIX1 synergizes with multiple PARP inhibitors across homologous recombination-proficient ovarian cancer cell lines, with high...

BioLineRx Shareholders Approve Board, Capital and Compensation Moves at 2026 AGM

Sep 24, 2026

BioLineRx Ltd. held its Annual General Meeting of Shareholders on September 23, 2026, in Israel, where investors approved all proposals presented in the proxy materials. The meeting’s decisions reinforce the current board structure, capital framework...

BioLineRx and Hemispherian to Showcase GLIX1 Glioblastoma Data and Trial Design at EANO 2026

Sep 10, 2026

On September 10, 2026, BioLineRx and Hemispherian announced that two abstracts on their lead asset GLIX1 were accepted for presentation at the European Association of Neuro-Oncology’s 2026 meeting in Rome. One mini-oral session will highlight preclin...

BioLineRx Raises $3.75 Million in August Registered Direct Offering and Warrant Deal

Aug 31, 2026

On August 27, 2026, BioLineRx entered into a securities purchase agreement for a registered direct offering of 480,696 ADSs and pre-funded warrants for up to 868,225 ADSs, alongside a concurrent private placement of unregistered warrants for up to 2,...

BioLineRx Advances GLIX1 Oncology Program and Posts Q2 2026 Results

Aug 31, 2026

BioLineRx reported unaudited financial results for the quarter ended June 30, 2026, on August 31, 2026, highlighting a net loss of $4.3 million on revenues of $0.3 million, increased R&D spending driven by its GLIX1 program, and cash and deposits of...

BioLineRx Raises $3.75 Million in Registered Direct Offering, Retires ATM Facility

Aug 28, 2026

BioLineRx Ltd., a clinical-stage biopharmaceutical company specializing in oncology and rare diseases with lead asset GLIX1 in glioblastoma and its approved stem cell mobilization drug APHEXDA for multiple myeloma, continues to advance its pipeline t...

BioLineRx Sets September 23, 2026 Shareholders Meeting to Boost Capital and Approve New Equity Awards

Aug 18, 2026

BioLineRx Ltd. reported on August 18, 2026 that it has called its Annual General Meeting of shareholders for September 23, 2026 at its Modi’in headquarters in Israel, with record date set at August 24, 2026 for holders of ordinary shares and American...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 17, 2026